Emerging in the arena of excess body fat management, retatrutide represents a distinct approach. Different from many available medications, retatrutide works as a double agonist, concurrently targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) binding sites. The simultaneous stimulation fosters seve